Aristeia Capital L.L.C. Makes New $10.89 Million Investment in Drugs Made In America Acquisition II Corp. $DMII

Aristeia Capital L.L.C. purchased a new stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,100,000 shares of the company’s stock, valued at approximately $10,890,000.

Several other large investors also recently made changes to their positions in DMII. Deltec Asset Management LLC bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth $495,000. Wolverine Asset Management LLC acquired a new position in Drugs Made In America Acquisition II in the 4th quarter worth $10,521,000. ABC Arbitrage SA bought a new position in Drugs Made In America Acquisition II during the 4th quarter worth about $396,000. Wealthspring Capital LLC bought a new position in Drugs Made In America Acquisition II during the 4th quarter worth about $4,049,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at about $7,817,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DMII shares. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Trading Up 0.1%

Shares of DMII stock opened at $10.10 on Thursday. The company has a fifty day simple moving average of $10.04. Drugs Made In America Acquisition II Corp. has a 1 year low of $9.86 and a 1 year high of $10.10.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.